Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AT7519M in relapsed mantle cell lymphoma
NCT01652144Phase 2Completed
- Sponsor
- Canadian Cancer Trials Group
- Start
- Sep 2012
- Primary completion
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of AT-7519 in mantle cell lymphoma (MCL), sponsored by Canadian Cancer Trials Group. Primary endpoint: Objective Response Rate at 24 months. Started Sep 2012; status: completed.
02
Drugs
AT-7519
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT01652144.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01652144.